Chugai Pharmaceutical Co., Ltd. (CHGCY)
| Market Cap | 86.58B +15.3% |
| Revenue (ttm) | 8.12B +5.7% |
| Net Income | 2.84B +10.3% |
| EPS | 1.73 +10.2% |
| Shares Out | n/a |
| PE Ratio | 30.44 |
| Forward PE | 25.18 |
| Dividend | 1.36 (5.54%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 11,243 |
| Average Volume | 239,921 |
| Open | 26.30 |
| Previous Close | 27.46 |
| Day's Range | 26.25 - 26.90 |
| 52-Week Range | 19.50 - 34.84 |
| Beta | 0.60 |
| RSI | 51.79 |
| Earnings Date | Apr 24, 2026 |
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular... [Read more]
Financial Performance
In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.
Financial numbers in JPY Financial StatementsNews
Q1 2026 Chugai Pharmaceutical Co Ltd Earnings Presentation Transcript
Q1 2026 Chugai Pharmaceutical Co Ltd Earnings Presentation Transcript
Chugai Pharmaceutical Earnings Call Transcript: Q1 2026
Q1 FY2026 delivered double-digit growth in revenue and profit, driven by strong Hemlibra and Nemluvio exports, new product launches, and increased royalty income. Performance was in line with expectations, with positive FX impact and robust pipeline progress.
Chugai Pharma Q1 Results Climb, Backs FY26 Outlook
(RTTNews) - Japan's Chugai Pharmaceutical Co., Ltd. (CHGCF.PK, 4519.T) reported Friday higher profit and revenues for its first quarter, and maintained fiscal 2026 outlook
Japanese drugmakers slump after Trump unveils discount drug website
Shares of Japanese pharmaceutical companies slumped in early Tokyo trading on Friday after U.S. President Donald Trump's website offering discounted prescription medicines went live.
Chugai Pharmaceutical Earnings Call Transcript: Q4 2025
Record FY2025 results with revenue up 7.5% and core operating profit up 12.1%, driven by strong exports and royalty income. FY2026 guidance projects further growth, with continued investment in R&D, digital transformation, and global partnerships.
Chugai Pharmaceutical Earnings Call Transcript: Q3 2025
Q3 FY2025 delivered strong revenue and profit growth, driven by robust domestic and overseas sales, especially from Hemlibra, Actemra, and new product launches. Strategic acquisitions and pipeline progress support a positive outlook, with full-year results expected to exceed last year.
Chugai Pharmaceutical Earnings Call Transcript: Q2 2025
Second quarter 2025 saw revenue and profit growth driven by strong domestic and overseas sales, especially for Actemra and Hemlibra. Five early-stage R&D projects were discontinued to focus resources, and a major JPY 80 billion R&D facility investment was announced. Guidance for key products was raised on robust demand.
Chugai Pharmaceutical Earnings Call Transcript: Q1 2025
Q1 2025 saw robust revenue and profit growth, driven by strong overseas sales of Hemlibra and Actemra, with operating margin at 48.4%. Key pipeline advances include NXT007 and orforglipron, while uncertainties remain around U.S. tariffs and biosimilar launches.
Chugai Pharmaceutical Earnings Call Transcript: Q4 2024
FY2024 saw record revenue and profit, driven by strong overseas sales, especially Hemlibra, offsetting domestic declines. The outlook for 2025 is positive, with continued growth expected from new products and a robust R&D pipeline, despite risks from generics and biosimilars.
Chugai Pharmaceutical Earnings Call Transcript: Q2 2024
Revenue declined due to the absence of RONAPREVE, but core business grew 10.9% year-over-year, with operating profit and net income both rising over 10% on strong HEMLIBRA and ACTEMRA exports. Operating margin improved to 47.5%, and full-year guidance anticipates record profits.